Development of the therapeutical strategy of inhibition of pancreatic fibrosis using Ptch1 peptide aiming improvement of immunotolerance in patients with pancreatic cancer
| Project/Area Number |
16K15593
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
Onishi Hideya 九州大学, 医学研究院, 准教授 (30553276)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中村 雅史 九州大学, 大学病院, 教授 (30372741)
中野 賢二 九州大学, 農学研究院, 特任教授 (00315061)
大内田 研宙 九州大学, 大学病院, 講師 (20452708)
山崎 章生 九州大学, 医学研究院, 共同研究員 (80404440)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | Ptch1ペプチド / Hedgehogシグナル / 膵癌 / 線維化 / リンパ球 / 免疫監視機構 / 癌浸潤リンパ球 / 抗腫瘍効果 / 免疫監視構築 / 抗腫瘍活性 / 自己免疫疾患 / ヘッジホッグシグナル / 活性化リンパ球 / TIL / 免疫寛容 / 膵線維化 / Ｈｅｄｇｅｈｏｇ阻害剤 |
|---|
| Outline of Final Research Achievements |
We used nude mice injected with mixture of pancreatic cancer cell line, ASPC-1 and cancer associated fibroblast subcutaneously. After tumor growing, activated lymphocytes were administrated intraperitoneally, and degree of fibrosis, tumor-infiltrated lymphocytes (TIL) number and tumor volume were estimated in control group and Ptch1 peptide group. Pancreatic fibrosis was reduced, TIL number was increased, and tumor volume was decreased in Ptch1 peptide group. These results suggest that Ptch1 peptide improves immunotolerance condition by decreasing pancreatic fibross and inducing TIL number.
|
Report
(3 results)
Research Products
(23 results)
